1. Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М., Атмосфера. 2008; с. 374–97.
2ю Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
3. Costerton JW et al. Scientific American 1978; 238: 86.
4. El-Azizi M, Rao S, Kanchanapoom T et al. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 2005; 4: 2.
5. Albini E, Belluco G, Berton M et al. In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Arzneim-Forsch Drug Res 1999; 49: 533–5.
6. Rizzato G. Antibiotics for aerosol intake in respiratory infections: pole position for tiamfenicol. L’Internista J 2001; 9: 120.
7. Lombardi A, Drago L, De Vecchi E et al. Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. Arzneimittelforschung 2001; 51 (3): 264–7.
8. Drago L, Fassina MC, Mombelli B et al. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. Chemotherapy 2000; 46 (4): 275–81.
9. Mazzei T. Thiamphenicol: pharmacokinetic and safety considerations. GIMMOC 2000; 4: 15–9.
10. Melillo G, Chiummariello A, Scala G. On the use of a new molecular combination of acetylcysteine with thiamphenicol glycinate in bronchopulmonary suppurations. G Ital Chemioter 1966; 13 (1): 156–60.
11. Bürgi H. Mucolytic and antibiotic effect of a new compound in chronic bronchitis. Chemotherapy 1975; 21 (3–4): 167–74.
12. Mayaud C, Lentschner C, Bouchoucha S et al. Thiamphenicol glycinate acetylcysteinate in the treatment of acute respiratory infections with mucostasis. Eur J Respir Dis (Suppl.). 1980; 111: 70–3.
13. Grassi C, De Benedetto F. Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. J Chemother 2002; 14 (3): 279–84.
14. Vysotiuk L, Hromova A. Fluimucyl-antibiotic IT: ability of antioxidant therapy for patients with acute attack of infectious chronic obstructive lung disease. Lik Sprava 2006; (1–2): 65–81.
15. Овчаренко C.И., Морозова Н.В. Эффективность применения Флуимуцил-антибиотика ИТ в лечении обострений ХОБЛ. Атмосфера. Пульмонология и аллергология. 2003; 3: 26–8.
16. Овчаренко C.И., Капустина В.А. Успешное применение ингаляционной формы Флуимуцил-антибиотика ИТ в комплексной терапии инфекционно-воспалительных заболеваний органов дыхания. Фарматека. 2010; 11 (205): 42–5.